Home HCP pJIA

 

Xatmep: The first and only FDA-approved methotrexate oral solution for the management of POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (pJIA) in pediatric patients.


  • Assured efficacy delivered with consistent potency.1
  • The first and only FDA-approved methotrexate oral solution for pJIA.
  • Oral solution provides consistent stability when stored as directed.2
  • No compounding or crushing tablets necessary.
  • No methotrexate injections necessary.
  • Body surface area-based dosing.